Rödel, Claus 1966-
Rödel, Claus
Claus Rödel wetenschapper
VIAF ID: 295861349 ( Personal )
Permalink: http://viaf.org/viaf/295861349
Preferred Forms
- 100 0 _ ‡a Claus Rödel ‡c wetenschapper
-
- 100 1 _ ‡a Rödel, Claus
- 100 1 _ ‡a Rödel, Claus
-
- 100 1 _ ‡a Rödel, Claus ‡d 1966-
- 100 1 _ ‡a Rödel, Claus
4xx's: Alternate Name Forms (6)
5xx's: Related Names (3)
- 551 _ _ ‡a Bamberg ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Klinikum Frankfurt am Main ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universität Heidelberg ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group | |
Albin Brunovský : 14 exlibris | |
Analysis of MRI and CT-based radiomics features for personalized treatment in locally advanced rectal cancer and external validation of published radiomics models | |
C-reactive protein to albumin ratio as prognostic marker in locally advanced non-small cell lung cancer treated with chemoradiotherapy | |
Einfluss der Behandlungscompliance auf den Erfolg der Radiochemotherapie des Analkarzinoms | |
Factors associated with hemorrhage of melanoma brain metastases after stereotactic radiosurgery in the era of targeted/immune checkpoint inhibitor therapies | |
Fractionation-dependent radiosensitization by molecular targeting of Nek1 | |
Gastrointestinal oncology, c2011: | |
Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy | |
High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer. oncological outcomes after a median 15-year follow-up | |
Individualized mould-based high-dose-rate brachytherapy for perinasal skin tumors: technique evaluation from a dosimetric point of view | |
Individuelle Dosimetrie der Nieren bei der Therapie des metastasierten kastrationsresistenten Prostatakarzinoms mit 177Lu-Prostataspezifischem Membranantigen (177Lu-PSMA) mittels konventioneller nuklearmedizinischer Diagnostik | |
Molecular markers to predict prognosis and treatment response in uterine cervical cancer | |
Movember health care initiative 2019: prostate cancer screening at the University Hospital Frankfurt | |
Neoadjuvant chemoradiotherapy for oral cavity cancer: predictive factors for response and interim analysis of the prospective INVERT-Trial | |
Patterns of care, toxicity and outcome in the treatment of salivary gland carcinomas: long-term experience from a tertiary cancer center | |
RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: a randomized multicenter phase II trial | |
Radioimmunotherapy: future prospects from the perspective of brachytherapy | |
Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK) | |
Short-term radiotherapy with 5 × 5 Gy followed by preoperative chemotherapy and resection in patients with locally advanced rectal carcinoma results in improved disease-free survival | |
Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited | |
Twenty years of experience of a tertiary cancer center in total body irradiation with focus on oncological outcome and secondary malignancies | |
Urologische Prostatakrebsvorsorge im Rahmen der Movember-Gesundheitsinitiative 2019 am Universitätsklinikum Frankfurt | |
Value of PET imaging for radiation therapy |